These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 29714564

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Medical device warning letter draft pilot; availability--FDA. Notice.
    Fed Regist; 1998 Aug 27; 63(166):45821-5. PubMed ID: 10182695
    [Abstract] [Full Text] [Related]

  • 23. Raising suspicions with the Food and Drug Administration: detecting misconduct.
    Hamrell MR.
    Sci Eng Ethics; 2010 Dec 27; 16(4):697-704. PubMed ID: 20842536
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
    Wagoner KG, Lazard AJ, Romero-Sandoval EA, Reboussin BA.
    Cannabis Cannabinoid Res; 2021 Dec 27; 6(6):559-563. PubMed ID: 34142863
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010-2020.
    Rathore AS, Li Y, Chhabra H, Lohiya A.
    J Pharm Innov; 2022 Aug 15; ():1-10. PubMed ID: 35992018
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The role of data audits in detecting scientific misconduct. Results of the FDA program.
    Shapiro MF, Charrow RP.
    JAMA; 1989 May 05; 261(17):2505-11. PubMed ID: 2704109
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003 May 05; 17(4):290-5. PubMed ID: 12899647
    [Abstract] [Full Text] [Related]

  • 32. Life After Research Misconduct.
    Galbraith KL.
    J Empir Res Hum Res Ethics; 2017 Feb 05; 12(1):26-32. PubMed ID: 28220722
    [Abstract] [Full Text] [Related]

  • 33. Administrative Actions for Noncompliance; Lesser Administrative Actions. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2016 Apr 04; 81(64):19033-6. PubMed ID: 27044118
    [Abstract] [Full Text] [Related]

  • 34. Clinical study reflections: another view: Commentary on: "Raising suspicions with the Food and Drug Administration: detecting misconduct".
    Spitzig P.
    Sci Eng Ethics; 2010 Dec 04; 16(4):705-11. PubMed ID: 21052860
    [Abstract] [Full Text] [Related]

  • 35. A review of US EPA and FDA requirements for electronic records, electronic signatures, and electronic submissions.
    Keatley KL.
    Qual Assur; 1999 Dec 04; 7(2):77-89. PubMed ID: 10992873
    [Abstract] [Full Text] [Related]

  • 36. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
    Zagrodney KAP, Sheikhan NY, Pinto A, Sheikhan T, Witek TJ.
    Pharmaceut Med; 2021 Jan 04; 35(1):31-38. PubMed ID: 33453042
    [Abstract] [Full Text] [Related]

  • 37. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
    Salas M, Martin M, Pisu M, McCall E, Zuluaga A, Glasser SP.
    Pharmaceut Med; 2008 Mar 01; 22(2):. PubMed ID: 24353430
    [Abstract] [Full Text] [Related]

  • 38. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
    Mohite N, Funtanilla V, Muzumdar J, Park T.
    Innov Pharm; 2021 Mar 01; 12(1):. PubMed ID: 34007685
    [Abstract] [Full Text] [Related]

  • 39. An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.
    Sams L, Slagle AF, Symonds T, Antonova J, Globe D.
    Value Health; 2023 Dec 01; 26(12):1675-1680. PubMed ID: 37748736
    [Abstract] [Full Text] [Related]

  • 40. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H.
    Int J Health Policy Manag; 2015 Aug 25; 4(12):813-21. PubMed ID: 26673465
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.